Skip to Content

Posts tagged with "Drug Industry History"

  • Drug Industry History

    Scientists Running Your Drug Company?

    There’s an interesting article that showed up in the Financial Times about the leadership of drug companies. Specifically, the number of them that are run by scientists (always lower than you would have thought) is dropping even further. “Only one large western pharmaceutical company will be run by a scientist (John Lechleiter of Lilly) Read More
  • Drug Development

    The Mechanical Chemist?

    We use a lot of automated equipment in the drug discovery business. There’s an awful lot of grunt work involved, and in many cases a robot arm is better suited to the task – transferring solutions, especially repetitive transfers of large numbers of samples, is the classic example. High-throughput screening would just not be possible… Read More
  • Drug Industry History

    The Equipment Graveyard

    The comment that showed up recently about unearthing an “original Cable and Wireless dephilostagenator” in a lab reminded me of the huge lab moving job I was in on some years ago. We were packing up the entire company’s research site and moving it to another spot in New Jersey (Bloomfield to Kenilworth), and this… Read More
  • Drug Assays

    Drugs For Bacteria: Really That Hard, Or Not?

    A few readers have told me that I’m being too hard on antibacterial drug discovery, at least on target-based efforts in the field. The other day I asked if anyone could name a single antibacterial drug on the market that had been developed from a target, rather than by screening or modification of existing drugs… Read More
  • Business and Markets

    Roche / Genentech: The Chase Is Over

    So Roche and Genentech have come to terms: $95 per share. They’d offered more last fall, but, well, it isn’t last fall any more. And this was still well above Roche’s recent offers, although they’d come up to $93 in public before this was announced this morning. Genentech shares had been climbing up to much… Read More
  • Business and Markets

    Merck Actually Does It

    So Merck wasn’t kidding about making a large deal, were they? When I used to work for Schering-Plough back in the 1990s, there were constant rumors, the whole eight years I spent there, about the company merging or being taken over. And as far as I know, those have never really ceased – until now… Read More
  • Alzheimer's Disease

    Does Glucophage Make Alzheimer’s Worse?

    Metformin, now there’s a drug story for you. It’s a startlingly small molecule, the sort of thing that chemists look and and say “That’s a real drug?” It kicked around in the literature and the labs in the 1960s, was marketed in Europe in the 1980s but was shopped around in the US for quite… Read More
  • Cancer

    Kinases: Hot or Not?

    For the last ten or fifteen years, untold amounts of time and money have been spent developing drugs to inhibit kinase enzymes. Just go take a look at KinasePro’s archives; that’ll give you the idea. Huge programs have been run at all the major drug companies, and any number of smaller ones have been founded… Read More
  • Business and Markets

    Sir James Black Vents, Therapeutically

    Today I can recommend this interview with Sir James Black, discoverer of propranolol, cimetidine, and more. He’s 83 and has a lot to say about the current state of the drug industry: He becomes agitated when discussing a Harvard Business Review article from 2008 by Jean-Pierre Garnier, the former chief executive of GlaxoSmithKline, on the… Read More
  • Chemical News

    A Long Tail Indeed

    A reader reminded me of this paper, which I meant to blog on when it came out last year. The authors looked over the entire Chemical Abstracts Service registry file – in theory, every compound that’s ever been reported in the chemical literature – and asked how many different chemical scaffolds make up the organic… Read More